KIT and cyclic hematopoiesis: Indeed, a pathogenic role for c‐kit+ cells in CH was recently suggested by the finding that imatinib, a tyrosine kinase inhibitor blocking c‐kit receptor, improves pulmonary arterial remodelling by decreasing the recruitment of c‐kit+ cells in pulmonary arterial lesions of hypoxic mice 6.